Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
ORGANIZATION
JPMA to Ask Abe Administration to Continue Former Dialogue with Pharmaceutical Industry: Dr Teshirogi
Dr Isao Teshirogi, president of the Japan Pharmaceutical Manufacturers Association (JPMA) and president of Shionogi, told Jiho in a recent interview that he plans to ask the new administration of Prime Minister Shinzo Abe to resume the “government/private-sector dialogue” that…
To read the full story
Related Article
ORGANIZATION
- Off-Year Price Revision Has Accomplished Mission: JPMA Exec
October 18, 2024
- JaDHA Inks MOU with DTA to Collaborate in DTx Push
October 16, 2024
- JaDHA Creates Hypothetical Case Collection to Push Two-Stage Approval of SaMD
October 11, 2024
- EFPIA Chief Sees Positive Signal from Japan Policymakers, Calls for Consistency
October 11, 2024
- EFPIA Japan Chair Urges All Players to Join Forces in Drug Loss Fight
October 10, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…